Current Landscape of Relapsed/ Refractory Multiple Myeloma
Panelists discuss how the current treatment landscape for relapsed/refractory multiple myeloma (R/R MM) includes standard options like such as IMiDs, PIs, and mAbs, while highlighting the emergence of novel therapies such as CAR T- cells and bispecific antibodies, which address unmet needs and offer potential advantages in treatment efficacy and patient outcomes.
Video content above is prompted by the following:
- Provide an overview of the current treatment landscape for R/R MM.
- Briefly discuss standard treatment options (e.g.eg, IMiDs, PIs,, and mAbs).
- Highlight the emergence of novel therapies (eg, CAR T-cells, ADCs antibody-drug conjugates, and bispecifics).
- Discuss the unmet needs in R/R MM treatment.
- Discuss challenges with current therapies (e.g.eg, resistance, and toxicities).
- Discuss patient populations with limited options.
- Introduce bispecific antibodies in the context of R/R MM.
- Discuss their Basic mechanism of action.
- Highlight currently approved bispecifics and those in late-stage development.
- Discuss the potential advantages of bispecific antibodies over other treatment modalities.
- How has the introduction of bispecifics changed your approach to treating R/R MM?
Related Content
